Glenmark Pharma has announced positive data from a phase 2a study of the molecule GBR 830, which was being studied for moderate-to-severe atopic dermatitis. In an interview to CNBC-TV18, Glenn Saldanha, CMD of the company spoke at length about the molecule.

Govt needs to be a strong enabler in pharma sector: Experts

Shereen Bhan speaks with top bosses from the pharma sector along with KT Rama Rao, Minister of IT, Telangana at Bioasia 2017 to discuss way forward for pharma sector in making India healthier.

New launches to drive earnings growth in FY18 & FY19: Glenmark

The company has a strong pipeline of products which the company, CMD Glenn Saldanha said adding that new launches will drive earnings for the company in FY18 and FY19. The company has no plans to raise further capital, he said.

Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal

USFDA has issued notice to the Hyderabad unit of Aurobindo Pharma and calming the nerves of the investors Surajit Pal of Prabhudas Lilladher says that it is a non-event and there is no need to worry.

See EBITDA margins at 25% over 10 years: Glenmark CMD

The company is aiming for at least one outlicensing deal in the next year and Saldanha also feels pharma giant will grow at a 15-20 percent CAGR over the next five years.

Aim is to prevent rampant use of antibiotics: P Lilladher

Hailing the government's move, Surajit Pal, pharma analyst at Prabhudas Lilladher, says the aim of regulation is to prevent rampant use of antibiotics. He says Abbott is likely to be severely impacted by the move as it has around 15.4 percent exposure to fixed-dosed combinations.

Sun's margins may reduce to 30-32% post merger: Surajit Pal

As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.

GBR 1302 could be an out-licencing opportunity: Glenmark

GBR 1302 molecule is a genetically engineered molecule and will be used for the study of breast cancer, says Michael Buschle.

Glenmark to get USD 9 mn upfront: CEO; stk at 52-wk high

Shares of Glenmark Pharmaceuticals rose over 2 percent to a 52-week high of Rs 512.65 on Monday morning following its agreement with Forest Laboratories on a collaboration for development of inhibitors to treat chronic inflammatory conditions, including pain.

Glenmark confident of US growth despite Tarka issue

In an interview with CNBC-TV18, Glenn Saldanha, managing director and chief executive officer of Glenmark Pharmaceuticals said,"Tarka is not a major contributor any more to the topline for the US business."